NeoGenomics

We’re excited to connect at #AACR26 and share how our end‑to‑end Pharma and Oncology Data Solutions capabilities are accelerating translational research and precision oncology. Book a meeting here: mailchi.mp/cda6649e6d3f/a…

Heading to #USCAP2026? Here’s a sneak peek of what you’ll find at booth #639. Book a meeting with us here: mailchi.mp/neogenomics/us… #Pathology #OncologyDiagnostics

Let’s make your career as lucky as a four-leaf clover! 🍀 Your next career opportunity could be just around the corner! Explore our open jobs & join a team that values hard work and growth: jobs.jobvite.com/neogenomics. #StPatricksDay #CareerOpportunities #LuckyToWorkHere #JoinOurTeam

Wherever the signal starts, you can find it with RaDaR ST: neogenomics.com/providers/onco… Its highly sensitive MRD technology detects tumor DNA, long before imaging, revealing the earliest signs of recurrence and supports timely, confident decisions. #NeoGenomics #PrecisionOncology

Join NeoGenomics at NextGen Omics Spatial & Data US 2026 for a special presentation: Mapping Immunotherapy Resistance: Unlocking Spatial Biology Insights Across the Tumor Microenvironment.

Join us at #USCAP2026! Visit booth 639 to learn about our latest innovations in cancer diagnostics, from solid tumor solutions to tech-only services. #Pathology #OncologyDiagnostics

NeoGenomics is headed to NextGen Omics Spatial & Data US 2026 in Boston on March 31–April 1! Visit us at Booth #27. We look forward to connecting with you in Boston!

This assay can help identify patients who may be eligible for a new targeted therapy, supporting precision oncology for patients with recurrent ovarian carcinoma, particularly those with platinum-resistant or platinum-refractory disease, for whom treatment options may be limited.

We are pleased to announce the launch of PD-L1 22c3 FDA for Ovarian Carcinoma: neogenomics.com/providers/test….

RaDaR® ST minimizes false positives and supports precise, timely care decisions: neogenomics.com/providers/onco…. #NeoGenomics #RaDaRST #PrecisionOncology #MRD . . . *Detection down to 1 part per million (ppm) under study-specific conditions

RaDaR® ST is supported by a growing foundation of clinical evidence. neogenomics.com/providers/onco…. #NeoGenomics #RaDaRST #PrecisionOncology #MRD

RaDaR® ST identifies the unique tumor profile of each patient to provide clear answers: neogenomics.com/providers/onco…. #NeoGenomics #RaDaRST #PrecisionOncology #MRD

Neo Comprehensive® – Myeloid Disorders, a CGP NGS assay, delivers clear and precise results for myeloid disorders, including MDS and CMML, helping clinicians make confident decisions. neogenomics.com/providers/test… #NeoGenomics #CancerTesting #OncologyInsights

𝐏𝐫𝐞𝐬𝐬 𝐑𝐞𝐥𝐞𝐚𝐬𝐞: #NeoGenomics has launched RaDaR® ST, our circulating tumor DNA (ctDNA) assay for detecting molecular residual disease (MRD): ir.neogenomics.com/news-events/pr…

𝐈𝐭’𝐬 𝐚𝐥𝐦𝐨𝐬𝐭 𝐡𝐞𝐫𝐞: RaDaR® ST, for clinical use, is a highly sensitive MRD test to detect circulating tumor DNA. 🔗 neogenomics.com/providers/onco… #NeoGenomics #RaDaRST #PrecisionOncology #MRD #MolecularResidualDisease

If we haven’t met, let’s fix that. NeoGenomics supports your oncology journey with data-backed insights that help close gaps in care and strengthen your strategy. Let’s connect and talk goals: lnkd.in/gzUvKeWw

𝐒𝐨𝐦𝐞𝐭𝐡𝐢𝐧𝐠 𝐛𝐢𝐠 𝐢𝐬 𝐜𝐨𝐦𝐢𝐧𝐠. Follow us to learn about our #MRD innovation from adjuvant therapy through surveillance: RaDaR® ST. #NeoGenomics #PrecisionOncology #RaDaRST

Don't miss this new PharmaBoardroom interview with Tony Zook, NeoGenomics Laboratories CEO, where he shares how decades in pharmaceutical leadership shape his view of diagnostics as the backbone of precision #oncology: pharmaboardroom.com/interviews/ton….

MRD detection with RaDaR ST can help improve clinical trial efficiency: neogenomics.com/partners/bioph… • Stratify and enrich clinical trial populations • Track response to experimental therapies • Use as a surrogate endpoint #NeoGenomics #PharmaPartners #ClinicalTrial #Oncology

PanTracer Pro streamlines molecular testing into a single order, eliminates order complexity, and ensures every patient receives the right tests. Explore PanTracer Pro: neogenomics.com/providers/onco… #NeoGenomics #CancerTesting #PanTracer #Molecular